Active Ingredient(s): Pemigatinib
FDA Approved: * April 17, 2020
Pharm Company: * INCYTE CORP
Category: Cancer

Pemigatinib, sold under the brand name Pemazyre, is an anti-cancer medication used for the treatment of bile duct cancer (cholangiocarcinoma).[1][2][3][4] Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading.[3] Pemigatinib belongs to a group of medicines called protein kinase inhibitors.[5] It works by blocking enzymes known as protein kinases, particularly... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Pemazyre 4.5 mg Oral Tablet
NDC: 50881-026
Incyte Corporation
Pemazyre 9 mg Oral Tablet
NDC: 50881-027
Incyte Corporation
Pemazyre 13.5 mg Oral Tablet
NDC: 50881-028
Incyte Corporation